FDA Expands Access of Teplizumab for Pediatric Type 1 Diabetes

The FDA expanded the therapeutic landscape for pediatric type 1 diabetes by approving teplizumab (Tzield) to delay the loss of endogenous insulin production in patients aged 8 to 17 years recently diagnosed with stage 3 of the disease. This decision, granted to Sanofi under an accelerated approval pathway, marks a significant milestone in clinical pharmacy as it targets the underlying autoimmune destruction of pancreatic beta cells rather than merely managing the resulting hyperglycemia.

The approval is anchored by data from the PROTECT (NCT03875729) study, a randomized, double-blind, placebo-controlled trial involving 328 patients who had been diagnosed with stage 3 type 1 diabetes within the previous 6 weeks. Researchers utilized C-peptide levels as a primary biomarker for beta cell function, finding that those who received the teplizumab regimen experienced a significantly smaller decline in insulin production over 78 weeks compared to the placebo group.

The Role of the Pharmacist

For pharmacists, understanding the distinct staging of type 1 diabetes is critical for identifying eligible patients and managing expectations for therapy. Stage 1 is characterized by the presence of 2 or more autoantibodies with normal blood sugar levels, and stage 2 involves abnormal blood sugar or dysglycemia but remains asymptomatic. Stage 3 represents the point of clinical diagnosis where significant beta cell destruction leads to overt symptoms like frequent urination and excessive thirst, necessitating the initiation of insulin therapy.^1-3

Although teplizumab was previously known for its ability to delay the onset of stage 3 in high-risk stage 2 patients, this newer indication focuses on preserving remaining beta cell function in those who have already transitioned to the clinical stage of the disease. This is particularly meaningful for pediatric populations because managing insulin therapy in very young children is complicated by variable physical activity and the inability to communicate symptoms of hypoglycemia.^1,2,4

The pharmacological mechanism of teplizumab involves its function as a CD3-directed humanized monoclonal antibody that binds to the T cell receptor CD3ε chain. This binding leads to partial T cell exhaustion and reduces the expansion of autoreactive CD8+ T cells, which are responsible for the immune-mediated destruction of insulin-producing cells.²

Pharmacists overseeing the administration of this therapy should note that it requires a consecutive 14-day course of daily intravenous infusions, with serum concentrations typically peaking on the final day of treatment. Monitoring for immunogenicity is also essential, as nearly 90% of participants in pediatric trials tested positive for antidrug antibodies by the second week of treatment, although these levels generally decline after the 12-week mark.²

Safety and Clinical Research in Type 1 Diabetes

Safety remains a paramount concern, and teplizumab carries a boxed warning regarding the risk of serious, life-threatening viral reactivation, specifically for Epstein-Barr virus and cytomegalovirus. Pharmacists should ensure that patients are tested for active infections prior to beginning the 14-day course. Beyond viral risks, the drug is associated with cytokine release syndrome, which typically manifests within the first 5 days with symptoms such as fever, fatigue, and nausea.¹

Clinical data also indicates that pediatric patients are at risk for transient lymphopenia and neutropenia, which can increase the likelihood of secondary infections. Interestingly, younger children have shown a higher incidence of vomiting compared to older cohorts, potentially because they may not communicate early nausea effectively enough to trigger pre-emptive antiemetic use.^1,2

Recent clinical research also highlighted the importance of early screening and the identification of new biomarkers that might indicate rapid disease progression. Although type 1 diabetes is traditionally associated with hyperglycemia, case reports have identified persistent, symptomatic hypoglycemia as a potential paradoxical biomarker for imminent progression to stage 3. This phenomenon may be caused by dysregulated insulin release or counter-regulatory failure during the early phases of beta cell destruction. As therapies like teplizumab become more integrated into pediatric care, the role of the pharmacist in monitoring these complex glycemic profiles and managing the rigorous 14-day infusion schedule will be vital in altering the natural history of type 1 diabetes for young patients.⁵

READ MORE: Diabetes Resource Center

Are you ready to elevate your pharmacy practice? Sign up today for our free Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips straight to your inbox.

REFERENCES

1. FDA approves drug for pediatric stage 3 type I diabetes. News release. FDA. June 12, 2026. Accessed June 15, 2026. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-pediatric-stage-3-type-i-diabetes

2. Gallagher A. FDA approves Tzield for patients 1 year of age to delay stage 3 type 1 diabetes. Drug Topics. April 22, 2026. Accessed June 15, 2026. https://www.drugtopics.com/view/fda-approves-tzield-for-patients-1-year-of-age-to-delay-stage-3-type-1-diabetes

3. Screen for Type 1. What is type 1 diabetes? Accessed June 15, 2026. https://www.screenfortype1.com/stages-of-type-1-diabetes/

4. CDC. Early treatment for type 1 diabetes. April 17, 2026. Accessed June 15, 2026. https://www.cdc.gov/diabetes/treatment/type-1-diabetes-early-treatment.html

5. Nagarapu A, Felton JL. Progression from Stage 1 to Stage 3 Type 1 Diabetes Characterized by Hypoglycemia. JCEM Case Rep. 2026;4(3):luaf317. Published 2026 Mar 12. doi:10.1210/jcemcr/luaf317